anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A method for providing centralized anatomic pathology services. A plurality of regional pathology laboratories is provided, each laboratory servicing a defined geographic region. A master storage (e.g., database) of pathology information is maintained, the storage being accessible by pathologists associated with any regional laboratory via a communications link. Tissue samples requiring pathology processing are collected from a medical entity located in a first geographic region by a regional pathology laboratory. The tissue is processed, and a tissue slide is created. A digital, diagnostic quality image of the tissue slide is created and stored in the master storage. A pathologist, who may be remotely located with respect to the first geographic region, is provided with access to the stored diagnostic image via the communications link, to enable diagnosis by the pathologist without physical possession of the slide. The digital, diagnostic quality image may be compressed before it is stored in the master storage. The diagnosis may be a primary or a secondary diagnosis. In the case of a secondary or supplemental diagnosis, the pathologist is provided with access to any prior analysis and annotations, stored in the master storage, relating to the diagnostic image. A system for implementing the method is also disclosed.
The induction of thermogenesis in brown adipose tissue is emerging as an attractive therapy for obesity and metabolic syndrome. However, the long-term efficacy and safety of clinical pharmaceutical agents have yet to be fully characterized. The transplantation of brown adipose tissue represents an alternative approach that might have a therapeutic effect by inducing a long-term increase in energy expenditure. However, limited tissue resources hinder the development of transplantation. Stem cell-based therapy and brown adipose tissue engineering, in addition to transplantation, represent alternative approaches that might resolve this problem. In this article, we discuss recent advances in understanding the mechanisms and applications of brown adipose tissue transplantation in the treatment of obesity and related metabolic disorders. Specifically, the induction of brown adipocytes and the fabrication of engineered brown adipose tissue as novel transplantation resources have long-term effects on ameliorating metabolic defects in rodent models. Additionally, we explore future prospects regarding the development of three-dimensional engineered brown adipose tissue and the associated challenges.
An application of a platycarya strobilacea infructescence extract. In particular, the invention provides the application of the platycarya strobilacea infructescence extract in preparation of an additive for increasing the yield of aquatic products and preventing and treating diseases of aquatic products, wherein the aquatic products includes fish or shrimp, the fish is epinepheius awoara. The platycarya strobilacea infructescence extract is a water extract of platycarya strobilacea infructescence. In the invention, the extract is prepared with water as an extraction solvent so that an extraction process is simple, economic, green, environment-friendly and safe. With the plant extract feed additive for breeding the epinepheius awoara, a growth promoting effect is achieved. A toxicity challenge test proves that the feed additive has an antibacterial capability on vibrio parahaemolyticus.
Ovarian endometriosis is characterized by the growth of endometrial tissue within the ovary, causing infertility and chronic pain. However, its pathophysiology remains unclear. Utilizing high-precision single-cell RNA sequencing, we profile the normal, eutopic, and ectopic endometrium from 34 individuals across proliferative and secretory phases. We observe an increased proportion of ciliated cells in both eutopic and ectopic endometrium, characterized by a diminished expression of estrogen sulfotransferase, which likely confers apoptosis resistance. After translocating to ectopic lesions, endometrial epithelium upregulates nicotinamide N-methyltransferase expression that inhibits apoptosis by promoting deacetylation and subsequent nuclear exclusion of transcription factor forkhead box protein O1, thereby leading to the downregulation of the apoptotic gene BIM. Moreover, epithelial cells in ectopic lesions elevate HLA class II complex expression, which stimulates CD4+ T cells and consequently contributes to chronic inflammation. Altogether, our study provides a comprehensive atlas of ovarian endometriosis and highlights potential therapeutic targets for modulating apoptosis and inflammation.
Hypothyroidism is the most frequent endocrine pathology. Although clinical or overt hypothyroidism has been traditionally associated to low T3 / T4 and high thyrotropin (TSH) circulating levels, other forms exist such as subclinical hypothyroidism, characterized by normal blood T3 / T4 and high TSH. In its different forms is estimated to affect approximately 10% of the population, especially women, in a 5:1 ratio with respect to men. Among its consequences are alterations in cardiac electrical activity, especially in the repolarization phase, which is accompanied by an increased susceptibility to cardiac arrhythmias. Although these alterations have traditionally been attributed to thyroid hormone deficiency, recent studies, both clinical trials and experimental models, demonstrate a fundamental role of TSH in cardiac electrical remodeling. Thus, both metabolic thyroid hormones and TSH regulate cardiac ion channel expression in many and varied ways. This means that the different combinations of hormones that predominate in different types of hypothyroidism (overt, subclinic, primary, central) can generate different forms of cardiac electrical remodeling. These new findings are raising the relevant question of whether serum TSH reference ranges should be redefined.
Strains of Bifidobacterium having the ability to survive in the intestinal tract and to produce glutamine in vivo, is new. Independent claims are included for the following: (1) one or more of (I) belonging to the species Bifidobacterium infantis for use in therapy; (2) a composition (II) comprising one or more of (I), in combination with a carrier; and (3) use of one or more of (I), for the preparation of a medicament for treatment of intensive care patients with multiple organ dysfunction and intestinal failure, for prophylaxis in chemotherapy patients and patients with inflammatory diseases, or for postoperative administration after major surgery. ACTIVITY : Gastrointestinal-Gen; Hepatoprotective; Antiinflammatory. MECHANISM OF ACTION : Producer of glutamine and arginine in vivo. Effects of Bifidobacterium strains on dextran sodium sulfate (DDS) induced colitis in rat was tested. Sprague dawley rates were administered orally with different strains of Bifidobacterium for 7 days prior to the induction of colitis (day 0) and were continuously administered for 7 days in combination with DDS (5% w/v dissolved in water). The degree of colitis were determined daily with disease activity index (DAI). Sampling was performed on day 14 and bacterial translocation and quantity in the intestine was determined. DAI was significantly lower in the group receiving B.infantis CURE 19 compared to the groups receiving Lactobacillus paracasei 8700:2 and L.gasseri LG1. After 6 and 7 days, orally administered bacterial strains were able to exercise positive effects by decreasing translocation on experimental colitis in rats. CURE 19 was more effective in counteracting the colitis than the others.
Limited data are available with regard to overdosage in human patients treated with VERQUVO. In VICTORIA, doses up to 10 mg have been studied. In a study of patients with preserved ejection fraction heart failure (left ventricular ejection fraction ≥45%), multiple doses of VERQUVO 15 mg have been studied and were generally well tolerated. In the event of an overdose, hypotension may result. Symptomatic treatment should be provided. VERQUVO is unlikely to be removed by hemodialysis because of high protein binding.
BACKGROUND: This retrospective observational study investigated the relationship between heart rate variability (HRV) and atrial fibrillation (AF) recurrence after pulmonary vein isolation (PVI) by cryoballoon or radiofrequency ablation (RF).
METHODS: We enrolled 497 patients who underwent PVI using first-generation cryoballoon (CB1), second-generation cryoballoon (CB2), or RF. We analyzed HRV as a surrogate for modulation of the intrinsic autonomic nervous system using 24‑h Holter recordings 1 or 2 days after the procedure and compared the recurrence and non-recurrence group with regard to ablation methods. Furthermore, we calculated recurrence-free survival (RFS) below/over HRV cut-off values for the whole study population and separately for each ablation method.
RESULTS: All except one of the five time-based HRV parameters analyzed were significantly lower in the non-recurrence group than in the recurrence group after CB2. Only a trend toward lower HRV for the non-recurrence group was found after RF and no remarkable differences were detected after CB1. The HRV parameters below their calculated cut-off were associated with a significantly higher RFS rate 2 years after CB2. This also applied to root mean sum of squared distance (rMSSD) and the percentage of adjacent NN interval differences greater than 50 ms (pNN50) after RF. No differences were found regarding CB1. Concerning rMSSD, the sensitivity, specificity, and difference in RFS increased when using cut-offs that were calculated including only CB2 patients. Multivariate cox regression analysis showed that low rMSSD values could independently predict AF recurrence after adjusting for covariates (hazard ratio: 0.50; p < 0.001).
CONCLUSION: Low values of rMSSD early after a PVI could independently predict AF recurrence, especially after CB2.
Patients receive placebo PO or through NJ, NG or G tube QD on day 1 of transplant conditioning regimen to 56 days post alloHCT. Patients undergo alloHCT at day 0.
The aim of this observational, non-interventional study was to observe and document for a 1-year period, the long-term use of galantamine and nootropics (memory enhancing drugs) over a 1 year period under conditions of daily routine in a typical patient population of patients with mild or moderate Alzheimer's dementia or with mixed dementia, i.e. Alzheimer's and cerebrovascular disease. The design of this prospective study was non-interventional and thus, there were no predefined specifications of diagnostic and therapeutic measures. The decision for treatment with either galantamine or a nootropic agent had to be made by the treating physician prior to the start of documentation. Patients were observed over a period of 12 months or until end of documentation (visit 1 = baseline; visit 2, 3 and 4 after approximately 2, 6 and 9 months, respectively; visit 5 after approximately 12 months or final visit at end of documentation). The following measures were to be documented: safety by documenting adverse and serious adverse events together with severity, outcome and causality to the treatment; tolerability; vital functions; Global Deterioration Scale (GDS) staging system assessing global functioning; Mini-Mental State Examination assessing cognitive functions; dementia-associated behavioural symptoms (unstable walking, vertigo, awakening at night, shouting/screaming at night, perambulating at night, aggressiveness, agitation, apathy/social retreat, delusions, hallucinations, behavior that poses a risk to self or others, and daytime tiredness); frequency of admissions to nursing homes or nursing services; caregiver's burden and time spent on caregiving (based on daily and weekly caregiving tasks); final evaluation of the therapy with galantamine or nootropics through the treating physician. Furthermore, this study aimed to gather knowledge on the differentiated use of the two treatment strategies considering the specific diagnosis of dementia (e.g. Alzheimer's disease only or mixed dementia, i.e. Alzheimer's disease and cerebrovascular disease) and risk profiles. Therapeutic measures were not predefined in the protocol but remained at the discretion of the treating physician. Therapy decisions were to be based on medical needs. The treatment regimen of galantamine (8 mg,16 mg, 24 mg retard capsule) or nootropic agents (e.g. ginkgo biloba, dihydroergotoxine, nicergoline, piracetam, or others) was to be in accordance with the recommendations given in the summary of product characteristics (SmPC).
PURPOSE: A composition containing Patinopecten yessoensis ingredient is provided to suppress plasma coagulation and ensure antibacterial effect. CONSTITUTION: A pharmaceutical composition for preventing or treating bacterial infectious diseases or thrombosis-associated diseases contains Patinopecten yessoensis ingredient as an active ingredient. The Patinopecten yessoensis extract is obtained using water including purified water, acetone, dimethyl ether, low alcohol of 1-4 carbon atoms or mixture solvent thereof. The used Patinopecten yessoensis is Patinopecten yessoensis, Pecten albicans, Chlamys farreri, Chlamys swifti, Patinopecten (Mizuhopecten) tokyoensis, or Lima sowerbyi. The composisiton contains 0.01-50 weight% of Patinopecten yessoensis extract. A health food for preventing and treating infectious diseases or thrombosis-associated diseases contains Patinopecten yessoensis extract as an active ingredient. The health food is manufactured in the form of powder, granule, tablet, capsule, syrup, or beverage.
The invention discloses a medicine composition for treating flu and a preparation method thereof. The medicine composition is mainly prepared from glycyrrhizic acid, baicalin, pseudoephedrine, taurine and other compounds. The invention has the advantages of simple medicine composition and exact curative effect; and animal experiments indicate that the medicine composition has strong inhibiting effect on influenza A virus and influenza B virus, and has the effects of killing various respiratory tract pathogenic bacteria to different degrees. The medicine composition has obvious and long-lasting antipyretic action and obviously relieves various cold symptoms, such as rhinorrhoea, snuffle, pains, cough and the like. The medicine composition has the action of synergy, can address both the symptoms and root causes against the causes and the symptoms of cold, and can obviously shorten the course of cold. The medicine composition can be made into any acceptable excipient in pharmaceutics.
PURPOSE:To obtain a polyion complex gel which can be prepd. easily in large quantities, is rich in moldability and gives a molded item such as a film which is uniform and has large strengths, by dissolving carboxymethylstarch and chitosan in an aq. formic acid soln., mixing them and removing the solvent. CONSTITUTION:Carboxymethylstarch and chitosan are dissolved in an aq. formic acid soln. and mixed and thereafter the solvent is removed therefrom. It is pref. that the concn. of formic acid in the aq. soln. used for preparing a polyion complex is 5wt.% or higher. The polyion complex can be suitably applied to foods, cosmetics, medicines and medical supplies by virtue of its safety.
Objective : Numerous epidemiological studies have identified a potential link between sepsis and a variety of autoimmune disorders. The primary objective of this study is to delve deeper into this connection, investigating the potential causal relationship between sepsis and autoimmune disorders through the application of Mendelian randomization (MR). Methods : To assess the potential genetic impact on sepsis risk relating to susceptibility toward immune-related outcomes, we used summary data from the largest European genome-wide association studies (GWAS) on these conditions using a two-sample MR framework. Single nucleotide polymorphisms-which had strong associations with the nine traits-were extracted from the GWAS and examined their effects in an extensive European sepsis GWAS (486,484 cases and 474,841 controls). We used inverse-variance weighted MR, weighted median, and MR Egger for analyses, supplementing these with sensitivity analyses and assessing level pleiotropy using MR methodologies. We also executed a reverse MR analysis to test sepsis' causal effects on the designated autoimmune traits. Results : With primary sclerosing cholangitis being the exception, our MR analysis suggests that susceptibility toward most autoimmune diseases does not affect sepsis risks. The reverse MR analysis did not validate any influence of sepsis susceptibility over other autoimmune diseases. Our primary inverse-variance weighted MR analysis outcomes found general confirmation through our sensitivity MR examinations. Variance in the exposures, as dictated by the single nucleotide polymorphism sets used as MR instruments, ranged between 4.88 × 10 -5 to 0.005. Conclusion : Our MR research, centered on a European population, does not validate a correlation between susceptibility to the majority of autoimmune disorders and sepsis risk. Associations discerned in epidemiological studies may owe partly to shared biological or environmental confounders. The risk susceptibility for primary sclerosing cholangitis does relate to sepsis risk, opening doors for personalized precision treatments in the future.
A system and method for removing personally identifiable information (PII) from medical data and ensuring strict compliance with privacy laws and regulations. The PII removal tool removes, deletes or redacts sensitive personally identifiable information, which may comprise any health care data that may be linked to any individual. The system and method is preferably applied to medical data, images, video, or other electronic media captured from medical procedures, endoscopes, or arthroscopic surgery. Artificial intelligence powered software and models are applied to the medical data for the detection of PII comprising patient names, medical history, faces, account numbers, digital identities, biometric data, or other sensitive personal information which may be linked to an individual. Medical data is re-written without PII and the system generates metadata describing the deleted PII. Privacy law compliant medical data is normalized, stored hierarchically, and transmitted to third party storage systems for analysis with software models for medical insights, anatomical recognition, surgical metrics, patient outcome, diagnosis and medical payment and billing.
TÜCHMI-001 is a single center, open label, randomized and controlled human pilot study to optimize controlled human malaria infection(CHMI) administered by PfSPZ Challenge. Volunteers will be inoculated with PfSPZ Challenge. Controls will receive the PfSPZ Challenge by ID administration. The remaining volunteers will receive the PfSPZ Challenge by IV administration. All volunteers recruited will be healthy adults aged between 18 and 45 years. Safety and infectivity data will be collected for each of the regimens and dose-levels.

Volunteers and clinical investigators will not be blinded to group allocation, however laboratory investigators processing blood films and samples for PCR analysis will be blinded to group allocation.
PURPOSE:To provide a method for treating hair, capable of easily, simply and effectively improving the quality of hair and reducing the damage to the hair even outside a bath. CONSTITUTION:When hair is treated with steam after or during a time when the hair is coated with a hair-treating agent, (A) a treating agent containing a compound of formula I (R<1> is H, methyl; R<2> is a 1-5C alkyl; (n) is 2-6), e.g. diethyleneglycol monoethyl ether, (B) a treating agent containing a compound of formula II (R<3> is H, a 1-4C alkyl; R<4> is COOH, SO3H), e.g. glycolic acid or lactic acid, and (C) a treating agent containing one or more of a naphthalene sulfonic acid compound, a benzophenone sulfonic acid compound, or an azulene sulfonic acid compound is used as the hair-treating agent. When the treating agent A is used, the generation of the split hair can especially be prevented. When the treating agent B is used, durable flexibility can be imparted to the hair. When the treating agent C is used, durable tension and stiffness can be given to the hair.
Patients will lie flat on their back on the examination couch with the arm in neutral position and the head turned slightly to the opposite side. Ultrasound scan will be performed sequentially starting from the base of the neck (supraclavicular fossa) to the upper part of the interscalene groove. The unique sonomorphology of the C7 transverse process will be used as the key anatomical landmark to identify the individual elements of the brachial plexus. Under ultrasound guidance, local anesthetic agents (a mixture of 2% lidocaine with 1:200,000 epinephrine and 0.5% levobupivacaine in a total of 30ml) will be injected at the interscalene groove and at the supraclavicular fossa in order to anesthetize the whole upper limb.
Infants, who were expected to be ≤2500 grams at birth (i.e. LBW) at time of enrollment, born to women with HIV-1 infection who received at least one dose of RAL 400 mg within 2 to 24 hours prior to delivery. The group also includes the mothers of these infants.
Insertion of intravaginal ring at enrollment. The intravaginal ring should stay in place for 12 consecutive weeks and will be removed by a physician at the Week 12 study visit.
Adult patients treated with unfractionated heparin aiming at aPTT 60-80 sec and/or anti-Xa level 0.3-0.7 iE/ml. All patients have Covid-19 proven by PCR or nose- or airway swab. Patients admitted to the ICU from the 15th of March 2020 until January 2022.
The use of ELIDEL Cream, 1% should be avoided on malignant or pre-malignant skin conditions. Malignant or pre-malignant skin conditions, such as cutaneous T-cell lymphoma (CTCL), can present as dermatitis.

ELIDEL Cream, 1% should not be used in patients with Netherton’s Syndrome or other skin diseases where there is the potential for increased systemic absorption of pimecrolimus. The safety of ELIDEL Cream, 1% has not been established in patients with generalized erythroderma.

The use of ELIDEL Cream, 1% may cause local symptoms such as skin burning (burning sensation, stinging, soreness) or pruritus. Localized symptoms are most common during the first few days of ELIDEL Cream, 1% application and typically improve as the lesions of atopic dermatitis resolve [see Adverse Reactions (6.1)].
Diabetic patients treated with SGLT2-I alone or in combination with other oral anti-diabetic (OAD) agents. Patients were considered in the SGLT2-I group if it was started at least 1 month prior to index hospitalization.